| Trial ID: | L1901 |
| Source ID: | NCT00612794
|
| Associated Drug: |
Exenatide Once Weekly
|
| Title: |
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: exenatide once weekly|DRUG: placebo
|
| Outcome Measures: |
Primary: To assess the safety and tolerability of exenatide administered once weekly by subcutaneous (SC) injection in subjects with type 2 diabetes mellitus., 10 weeks | Secondary: To assess the pharmacokinetics of exenatide administered once weekly by SC injection in subjects with type 2 diabetes mellitus., 10 weeks|To explore the pharmacodynamics of exenatide administered once weekly by SC injection in subjects with type 2 diabetes mellitus regarding the following: *fasting and postprandial glucose concentrations; *HbA1c; *Body weight., 10 weeks
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-09
|
| Completion Date: |
2008-05
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-24
|
| Locations: |
Research Site, Fukuoka, Japan|Research Site, Kanagawa, Japan|Research Site, Osaka, Japan|Research Site, Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00612794
|
